- Home
- ELP vs LEGN Comparison
ELP vs LEGN Comparison
Compare ELP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELP
- LEGN
- Stock Information
- Founded
- ELP 1954
- LEGN 2014
- Country
- ELP Brazil
- LEGN United States
- Employees
- ELP N/A
- LEGN N/A
- Industry
- ELP Electric Utilities: Central
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ELP Utilities
- LEGN Health Care
- Exchange
- ELP Nasdaq
- LEGN Nasdaq
- Market Cap
- ELP 6.2B
- LEGN 5.4B
- IPO Year
- ELP 1997
- LEGN 2020
- Fundamental
- Price
- ELP $8.96
- LEGN $34.99
- Analyst Decision
- ELP
- LEGN Strong Buy
- Analyst Count
- ELP 0
- LEGN 12
- Target Price
- ELP N/A
- LEGN $73.36
- AVG Volume (30 Days)
- ELP 214.9K
- LEGN 980.0K
- Earning Date
- ELP 08-06-2025
- LEGN 08-11-2025
- Dividend Yield
- ELP 4.93%
- LEGN N/A
- EPS Growth
- ELP 30.24
- LEGN N/A
- EPS
- ELP 0.19
- LEGN N/A
- Revenue
- ELP $4,381,150,343.00
- LEGN $796,838,000.00
- Revenue This Year
- ELP N/A
- LEGN $70.75
- Revenue Next Year
- ELP $6.59
- LEGN $52.47
- P/E Ratio
- ELP $11.34
- LEGN N/A
- Revenue Growth
- ELP 8.47
- LEGN 74.75
- 52 Week Low
- ELP $5.72
- LEGN $27.34
- 52 Week High
- ELP $9.34
- LEGN $57.94
- Technical
- Relative Strength Index (RSI)
- ELP 51.83
- LEGN 41.57
- Support Level
- ELP $8.80
- LEGN $34.14
- Resistance Level
- ELP $8.99
- LEGN $36.17
- Average True Range (ATR)
- ELP 0.15
- LEGN 1.09
- MACD
- ELP -0.01
- LEGN -0.04
- Stochastic Oscillator
- ELP 55.26
- LEGN 20.10
About ELP Companhia Paranaense de Energia (COPEL)
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.